A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
- Johnson, Barry C
- Pauly, Gary T
- Rai, Ganesha
- Patel, Disha
- Bauman, Joseph D
- Baker, Heather L
- Das, Kalyan
- Schneider, Joel P
- Maloney, David J
- Arnold, Eddy
- Thomas, Craig J
- Hughes, Stephen H
DOIAbstract
The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis. In contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clinically relevant RT mutants. Many structural analogues of rilpivirine are described in the patent literature, but detailed analyses of their antiviral activities have not been published. This work addresses the ability of several of these analogues to inhibit the replication of wild-type (WT) and drug-resistant HIV-1.status: publishe